PDCD1 and neoplasm: Since not all antigens caused by somatic mutations can be processed, presented, and recognized by T cells, TNB is considered as a better biomarker than tumor mutation burden (TMB) for predicting the efficiency of anti-PD1/PDL1 therapy (Coulie et al., 2014).